Stem cell blood filter tested for liver failure

NCT ID NCT06904755

Recruiting now Disease control Sponsor: Kebo Zhong Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early study tests whether using mesenchymal stem cells in a blood purification device is safe and can help adults with liver failure. Ten participants will receive the treatment alongside standard care. Researchers will track survival at 28 days and check for side effects. The stem cells stay outside the body and do not enter the patient.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: mesenchymal stem cells (used outside the body in a blood purification device)
What this could lead to: If it works, this could point toward a new way to support liver function and improve survival in liver failure without needing a transplant.
What could go wrong: This is a very early Phase 1 trial with only 10 people, so it is too small to prove effectiveness. The cells work outside the body, and the main goal is safety, not a cure.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACUTE LIVER FAILURE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acute liver failure liver failure

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

LIVER FAILURE

Contacts and locations

Locations

Zhujiang hospital
RECRUITING

Guangzhou, Guangdong, 510000, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.